Clinical trials: Stomach Adenocarcinoma
Gastric Adenocarcinoma
S-1, Cisplatin-based Chemoradiotherapy, Induction Chemotherapy, Locally Advanced Gastric Adenocarcinoma
Currently, for further improved survival outcome, new cytotoxic compounds such as irinotecan and docetaxel have been combined with 5-FU/cisplatin.
- Trial name
- NCT02495493
- Testing
- Induction DCS chemotherapy
- Where
- South Korea
- Volunteers
- 42 people
- Sponsor
- Yonsei University
Adenocarcinoma of the Gastroesophageal Junction, Diffuse Gastric Adenocarcinoma
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
This phase II clinical trial studies how well Akt inhibitor MK2206 works in treating patients with advanced gastric or gastroesophageal junction cancer.
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Diffuse Gastric Adenocarcinoma, Gastric Intestinal Type Adenocarcinoma, Gastric Mixed Adenocarcinoma
- Trial name
- NCT01260701
- Testing
- Akt Inhibitor MK2206
- Where
- 187 sites in United States, Canada
- Volunteers
- 75 people
- Sponsor
- National Cancer Institute (NCI)
Selected Advanced Solid Tumors, Colorectal Cancer (CRC)
SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors
This Phase 1, open-label study will evaluate two investigational radiopharmaceuticals in adults with selected advanced or metastatic solid tumors.
- Conditions
- Selected Advanced Solid Tumors, Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Biliary Tract Cancer (BTC)
- Trial name
- NCT07812805
- Testing
- SKL35501, SKL35502
- Where
- 5 sites in United States, South Korea
- Volunteers
- 100 people
- Sponsor
- SK Life Science, Inc.
Gastric Adenocarcinoma With Peritoneal Carcinomatosis, Siewert Type II Adenocarcinoma of Esophagogastric Junction With Peritoneal Carcinomatosis
Catumaxomab for Treatment of Peritoneal Carcinomatosis in Patients With Gastric Adenocarcinomas
The purpose of this study is to determine the efficacy of catumaxomab by determination of the rate of macroscopic complete remissions of peritoneal carcinomatosis after treatment with one cycle (four doses) of catumaxomab…
- Conditions
- Gastric Adenocarcinoma With Peritoneal Carcinomatosis, Siewert Type II Adenocarcinoma of Esophagogastric Junction With Peritoneal Carcinomatosis, Siewert Type III Adenocarcinoma of Esophagogastric Junction With Peritoneal Carcinomatosis
- Trial name
- CatuNeo (NCT01504256)
- Testing
- catumaxomab, Fluorouracil, leucovorin, oxaliplatin, docetaxel, Fluorouracil, leucovorin, oxaliplatin, docetaxel
- Where
- Germany
- Volunteers
- 42 people
- Sponsor
- AIO-Studien-gGmbH
Gastric Cancer, Pancreatic Ductal Adenocarcinoma
A Phase 1 Study of LCAR-C182A Cells in the Treatment of Advanced Gastric Cancer and Pancreatic Ductal Adenocarcinoma
This is an open label, single center, single arm phase 1 study to evaluate the safety , tolerability, pharmacokinetics and efficacy and immunogenicity of LCAR-C182A cells targeting Claudin18.2 in the treatment of patients with…
- Trial name
- NCT03890198
- Testing
- LCAR-C182A cells
- Where
- China
- Volunteers
- 2 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Peritoneal Carcinomatosis, Peritoneal Metastases
CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)
This is an open-label, dose-escalation, phase I trial of the safety and efficacy of anti-CEA intraperitoneal CAR-T infusions for treatment in patients with CEA-expressing adenocarcinoma peritoneal metastases or malignant ascites.
- Conditions
- Peritoneal Carcinomatosis, Peritoneal Metastases, Colorectal Cancer, Gastric Cancer
- Trial name
- NCT03682744
- Testing
- anti-CEA CAR-T cells
- Where
- 2 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sorrento Therapeutics, Inc.
Gastric Cancer, Esophagogastric Junction Disorder
Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients
Treating Gastric Cancer and Esophagogastric junction adenocarcinoma Patients with MET gene amplifications with Savolitinib
- Trial name
- NCT04923932
- Testing
- Savolitinib
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Hutchison Medipharma Limited
Breast Cancer, Gastric Cancer
Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab
The purpose of the study is to assess the safety, tolerability and preliminary antitumor activity of zanidatamab in combination with docetaxel in participants with human epidermal growth factor receptor 2 (HER2)-positive breast…
- Conditions
- Breast Cancer, Gastric Cancer, Gastroesophageal Junction Cancer
- Trial name
- NCT04276493
- Testing
- Zanidatamab, Docetaxel, Tislelizumab
- Where
- 21 sites in China, South Korea and 1 more
- Volunteers
- 71 people
- Sponsor
- BeiGene
Gastric Neoplasm, Gastroesophageal Junction Adenocarcinoma
OPPOSITE: Outcome Prediction of Systemic Treatment in Esophagogastric Carcinoma
Patients with locally advanced, resectable gastric or esophagogastric junction adenocarcinoma will receive a biopsy of the primary tumor, followed by standard-of care neoadjuvant systemic treatment; after neoadjuvant therapy…
- Conditions
- Gastric Neoplasm, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma, Gastric Adenocarcinoma
- Trial name
- OPPOSITE (NCT03429816)
- Testing
- Biopsy
- Where
- 2 sites in Germany
- Volunteers
- 120 people
- Sponsor
- University Hospital Heidelberg
Gastric Cancer
IN10018 Monotherapy or in Combination With Docetaxel in Gastric or GEJ Adenocarcinoma
This is a phase I, multi-center clinical trial to evaluate the safety, tolerability, antitumor activities and pharmacokinetics of IN10018 as monotherapy or in combination with docetaxel in previously-treated locally advanced or…
- Trial name
- NCT05327231
- Testing
- IN10018, Docetaxel
- Where
- 8 sites in China
- Volunteers
- 33 people
- Sponsor
- InxMed (Shanghai) Co., Ltd.
Immune Suppression, Gastric Cancer
Nivolumab Combined With SOX Used in the Perioperative Treatment
To evaluate the pathological complete response rate (pCR) of nivolumab combined with SOX (oxaliplatin + S-1) for neoadjuvant therapy of resectable gastric and gastroesophageal junction adenocarcinoma;
- Trial name
- NCT05739045
- Testing
- nivolumab combined with SOX
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Xiangdong Cheng
Advanced Gastrointestinal (GI) Malignancies, Hepatocellular Carcinoma
Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma
Phase 1: Assessment of safety and tolerability of ADI-PEG 20 in combination with folinic acid (leucovorin), fluorouracil and oxaliplatin (FOLFOX) in advanced GI malignancies.
- Conditions
- Advanced Gastrointestinal (GI) Malignancies, Hepatocellular Carcinoma, Gastric Cancer, Colorectal Cancer
- Trial name
- NCT02102022
- Testing
- ADI-PEG 20 plus modified FOLFOX6
- Where
- 35 sites in United States, China and 4 more
- Volunteers
- 140 people
- Sponsor
- Polaris Group
Stomach Cancer, Stomach Neoplasm
Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients
The primary objective is to evaluate six months survival rate and quality of life at 4 months of ramucirumab alone or in combination with paclitaxel in patients aged 70 years or more who have stomach or GEJ adenocarcinoma and…
- Conditions
- Stomach Cancer, Stomach Neoplasm, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
- Trial name
- SOCRATE (NCT03760822)
- Testing
- Ramucirumab, Paclitaxel
- Where
- 38 sites in France
- Volunteers
- 112 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Recurrent Malignant Solid Neoplasm, Stage IV Breast Cancer
Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites
The study designed is to evaluate the safety of Canady Helios™ Cold Plasma Scalpel (CHCPS) in patients with solid tumors with carcinomatosis scheduled to undergo surgical resection for cytoreduction.
- Conditions
- Recurrent Malignant Solid Neoplasm, Stage IV Breast Cancer, Stage IV Prostate Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT04267575
- Testing
- Canady Helios Cold Plasma Scalpel
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Jerome Canady, M.D.
Metastatic Esophageal Carcinoma, Advanced Unresectable Gastric Adenocarcinoma
A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer
Participants will receive study treatment with agenT-797, botensilimab, balstilimab, ramucirumab, and paclitaxel. When participants start each agent will depend on how their disease is affecting them.
- Conditions
- Metastatic Esophageal Carcinoma, Advanced Unresectable Gastric Adenocarcinoma, Metastatic Gastric Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT06251973
- Testing
- AgenT-797, Botensilimab, Balstilimab
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer
This study is a prospective, open-label, phase II clinical trial that aims to enroll patients with locally advanced gastric adenocarcinoma who have not received any prior treatment and are candidates for surgery.
- Trial name
- NCT06385873
- Testing
- RC48, Adebrelimab, Apatinib
- Volunteers
- 32 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Gastric Cancer, Signet Ring Cell Carcinoma
Mechanism of Gastric Signet Ring Cell Carcinoma Based on Microproteomics
Gastric signet ring cell carcinoma (GSRCC) possesses unique epidemiology and pathogenesis in the field of cancer, but its incidence is low.
- Trial name
- NCT05985577
- Testing
- Without any intervention
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Zhejiang Cancer Hospital
Metastatic Gastro-esophageal Adenocarcinoma
Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy
The goal of this clinical trial is to evaluate if bemarituzumab in combination with different standard of care chemotherapies enhance tumor response in patients with FGFR2b-positive advanced or metastatic adenocarcinoma of the…
- Trial name
- NCT06680622
- Testing
- bemarituzumab, paclitaxel, ramucirumab, bemarituzumab, irinotecan, bemarituzumab, trifluridine/tipiracil
- Where
- 35 sites in Germany
- Volunteers
- 126 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Advanced Solid Tumors, Glioblastoma
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
Prospective, open-label, dose-ranging, uncontrolled phase I/II study of Lurbinectedin in combination with irinotecan. The study will be divided into two stages: a Phase I dose escalation stage and a Phase II expansion stage.
- Conditions
- Advanced Solid Tumors, Glioblastoma, Soft Tissue Sarcoma (Excluding GIST), Endometrial Carcinoma
- Trial name
- NCT02611024
- Testing
- Lurbinectedin, Irinotecan
- Where
- 23 sites in United States, France and 4 more
- Volunteers
- 316 people
- Sponsor
- PharmaMar
Gastrointestinal Neoplasms, Adenocarcinoma
A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer
The Phase 1b study is an open-label, multicenter dose escalation study designed to assess the safety, tolerability, immunogenicity and recommended phase 2 dose (RP2D) of IMU-131.
- Trial name
- NCT02795988
- Testing
- IMU-131, Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and capecitabine.
- Where
- 22 sites in Georgia, India and 5 more
- Volunteers
- 64 people
- Sponsor
- Imugene Limited
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.